中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

嗜肝病毒阴性肝病的病因分析

郝大昂 刘晔 颜学兵

引用本文:
Citation:

嗜肝病毒阴性肝病的病因分析

DOI: 10.3969/j.issn.1001-5256.2020.12.019
基金项目: 

国家自然科学基金(81371867); 国家级十三五计划国家科技重大专项项目(2018111010); 江苏省医学科技专项-新型临床诊疗技术攻关(BL2014033); 江苏省医学重点人才培养基金(BRA2015506); 

详细信息
  • 中图分类号: R575

An etiological analysis of liver diseases with negative hepatotropic virus

Research funding: 

 

  • 摘要:

    目的分析嗜肝病毒阴性肝病的病因,为肝脏疾病的临床诊治提供思路。方法回顾性分析2018年7月-2019年12月在徐州医科大学附属医院感染科收治的113例嗜肝病毒阴性肝病患者的临床资料及肝脏穿刺活组织检查结果,根据性别分为男性组(n=41)和女性组(n=72),根据年龄分为青年组(n=42)、中年组(n=56)和老年组(n=15)。计数资料组间比较采用χ2检验。结果 113例嗜肝病毒阴性肝病患者中,最终明确病因病例111例(98. 23%)。非酒精性脂肪性肝病(NAFLD) 43例(38. 05%)、药物性肝损伤(DILI) 40例(35. 40%)、自身免疫性肝病(AILD) 16例(14. 15%)、酒精性肝病(ALD) 8例(7. 08%)、胆道系统疾病3例(2. 65%)、其他系统疾病累及肝脏1例(0. 88%)。男性患者以NAFLD(53. 49%)、ALD(100%)、DILI(15. 00%)为主,女性患者以DILI(85. 00%)、NAFLD(46. 51%)、AILD(93. 75%)为主。DILI中女性患者明显多于男性(χ2=40. 000,P<0. 001)...

     

  • [1] SHAO PP,SUN QL,CHENG J,et al. Epidemiological and clinical characteristics analysis in 1 062 cases of elderly liver diseases[J]. Acta Univ Med Anhui,2016,51(4):541-543.(in Chinese)邵盼盼,孙秋林,程君,等.1062例老年肝病患者临床流行病学及临床特点分析[J].安徽医科大学学报,2016,51(4):541-543.
    [2] LIU XC,ZHAO T,ZHAO ZM,et al. Incidence and trends of viral hepatitis in China[J]. J Prev Med,2018,30(5):433-437.(in Chinese)刘小畅,赵婷,赵志梅,等.中国居民病毒性肝炎流行趋势分析[J].预防医学,2018,30(5):433-437.
    [3] CHEN ZJ,ZHAO YF. Ultrasound guided percutaneous biopsy in diagnosis of liver disease and its clinical application value[J]. China J Prac Med,2014,41(10):17-19.(in Chinese)陈中建,赵永福.彩超引导下经皮穿刺活检对肝脏病变的诊断及其临床应用价值[J].中国实用医刊,2014,41(10):17-19.
    [4] Fatty Liver and Alcoholic Liver Disease Group,Hepatology Branch,Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病组.酒精性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):939-946.
    [5] Fatty Liver and Alcoholic Liver Disease Group,Hepatology Branch,Chinese Medical Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
    [6] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1769.
    [7] Chinese Society of Rheumatology. Guidelines for diagnosis and treatment of autoimmune liver disease[J]. Chin J Rheumatol,2011,15(8):556-558.(in Chinese)中华医学会风湿病学分会.自身免疫性肝病诊断和治疗指南[J].中华风湿病学杂志,2011,15(8):556-558.
    [8] OHARA H,OKAZAKI K,TSUBOUCHI H,et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012[J].J Hepatobiliary Pancreat Sci,2012,19(5):536-542.
    [9] Chinese Society of Rheumatology. Guidelines for diagnosis and treatment of Sjogren’s syndrome[J]. Chin J Rheumatol,2010,14(11):766-768.(in Chinese)中华医学会风湿病学分会.干燥综合征诊断及治疗指南[J].中华风湿病学杂志,2010,14(11):766-768.
    [10] DING LM,WANG F,PU LS,et al. Etiology of 202 patients with abnormal liver function tests[J]. J Pract Hepatol,2019,22(6):856-859.(in Chinese)丁利敏,王飞,朴莲淑,等.202例肝功能异常患者病因分析[J].实用肝脏病杂志,2019,22(6):856-859.
    [11] RINELLA ME. Nonalcoholic fatty liver disease:A systematic review[J]. JAMA,2015,313(22):2263-2273.
    [12] DIEHL AM,DAY C. Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med,2017,377(21):2063-2072.
    [13] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
    [14] BYRNE CD,TARGHER G. NAFLD:A multisystem disease[J]. J Hepatol,2015,62(1 Suppl):s47-s64.
    [15] MUSSO G,GAMBINO R,CASSADER M,et al. Meta-analysis:Natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity[J]. Ann Med,2011,43(8):617-649.
    [16] MUSSO G,GAMBINO R,TABIBIAN JH,et al. Association of non-alcoholic fatty liver disease with chronic kidney disease:A systematic review and meta-analysis[J]. PLo S Med,2014,11(7):e1001680.
    [17] WILLIAMS VF,TAUBMAN SB,STAHLMAN S. Non-alcoholic fatty liver disease(NAFLD),active component,U. S. Armed Forces,2000-2017[J]. MSMR,2019,26(1):2-11.
    [18] ALLEN AM,THERNEAU TM,LARSON JJ,et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death:A 20 year-community study[J]. Hepatology,2018,67(5):1726-1736.
    [19] LEE C,KIM J,JUNG Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Cells,2019,8(10):1259.
    [20] STINE JG,LEWIS JH. Drug-induced liver injury:A summary of recent advances[J]. Expert Opin Drug Metab Toxicol,2011,7(7):875-890.
    [21] WANG PH,HE XD,CAO JZ,et al. Comparing the clinical characteristics of IgG4-related sclerosing cholangitis with primary sclerosing cholangitis[J]. Chin J Hepatobiliary Surg,2016,22(5):315-319.(in Chinese)王鹏辉,何小东,曹建中,等.原发性硬化性与IgG4相关硬化性胆管炎临床特征比较[J].中华肝胆外科杂志,2016,22(5):315-319.
    [22] YANG Y,LUO C,HUANG QL,et al. Research progress of immunoglobulin G4-related sclerosing cholangitis[J]. Med J Chin PLA,2019,44(10):881-886.(in Chinese)杨屹,罗晨,黄启林,等.IgG4相关性硬化性胆管炎研究的进展[J].解放军医学杂志,2019,44(10):881-886.
  • 加载中
计量
  • 文章访问数:  4076
  • HTML全文浏览量:  17
  • PDF下载量:  73
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-06-16
  • 出版日期:  2020-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回